close
BRIEFING ON RNA TRIALS – JANUARY 2019
News

BRIEFING ON RNA TRIALS – JANUARY 2019

RNA science is now translated into new therapies…
Last August, the FDA approved the first RNAi therapy, Onpattro®…
RNA drugs allow precised silencing or activation of genes…
RNA drugs can address a wide range of common and rare diseases…
More than 60 rare or common diseases are currently  targeted…. 

BioPharmAnalyses and Octopusyx BioConsulting
are proud to announce the launch of the first issue of

« BRIEFING ON RNA TRIALS »

You need to get an update on the clinical portfolio of RNA products?
You need insights to assist you in your decision-making in RNA drugs?
You need to identify the most advanced companies?
You need to in-license a new candidate?
You need to identify licensed products ?

Briefing on RNA Trials is the up-dated report on RNA products you need to have.
It gives you an accurate overview
to explore the latest trials and publications in this dynamic area.

« BRIEFING ON RNA TRIALS » BY NUMBERS 

86 pages detailing 101 clinical trials conducted in 44 countries

42 companies and academic institutions developing 78 RNA products
(antisense oligonucleotides, RNAi/siRNA, microRNA, mRNA…) 

55 targets and 65 diseases in a wide range of therapeutic areas
(cancers, cardiovascular and metabolic diseases, infectious diseases,
genetic diseases, ophthalmological diseases….)

 The trials presented in this study have been registered and updated on Clinicaltrials.gov from 01/01/2017 to 12/31/2018.

Click here to get a Briefing on RNA trials sample

 

« BRIEFING ON RNA TRIALS »
(Updated 12/31/2018)

Order your copy before March 1st and get more than 40% discount

€ 890 instead of €1490 

Click here to receive the report
or
Fill in the subscription form with special discount
The report and the bill will be provided by email upon receipt of your payment.

spacer

COMMENTS ARE OFF THIS POST